rizatriptan and Addiction, Opioid

rizatriptan has been researched along with Addiction, Opioid in 1 studies

rizatriptan: structure given in first source; RN given refers to benzoate

Research

Studies (1)

Authors

Clinical Trials (5)

Trial Overview

Trial Outcomes

Pain Relief at 2 Hours During the First Migraine Attack Period

Patients reporting pain relief defined as a reduction of headache severity from grades 2 or 3 (moderate or severe) at baseline to grades 0 or 1 (no headache or mild) at 2 hours after initial dosing for the first migraine attack (NCT00899379)
Timeframe: 2 hours

Pain Relief at 2 Hours During the Fourth Migraine Attack Period

Patients reporting pain relief defined as a reduction of headache severity from grades 2 or 3 (moderate or severe) to grades 0 or 1 (no headache or mild) at 2 hours after dosing for the fourth migraine attack (NCT00899379)
Timeframe: 2 hours

Pain Relief at 2 Hours During the Second Migraine Attack Period

Patients reporting pain relief defined as a reduction of headache severity from grades 2 or 3 (moderate or severe) to grades 0 or 1 (no headache or mild) at 2 hours after dosing for the second migraine attack (NCT00899379)
Timeframe: 2 hours

Pain Relief at 2 Hours During the Third Migraine Attack Period

Patients reporting pain relief defined as a reduction of headache severity from grades 2 or 3 (moderate or severe) to grades 0 or 1 (no headache or mild) at 2 hours after dosing for the third migraine attack (NCT00899379)
Timeframe: 2 hours

Functional Status at 2 Hours After Dose

Patients with no functional disability measured by the level of impairment to daily activities at 2 hours after treatment. Each patient rated functional disability on a 4-grade scale (0 = no functional disability; 1 = daily activities mildly impaired; 2 = daily activities severely impaired; 3 = unable to carry out daily activities, requires bed rest). (NCT00898677)
Timeframe: 2 hours after dose

Nausea at 2 Hours After Dose

Patients who recorded the presence or absence of nausea 2 hours after dose (NCT00898677)
Timeframe: 2 hours after dose

Pain Free at 2 Hours After Dose

Patients pain free (defined as a reduction of headache severity to grade 0 [no pain]) at 2 hours after treatment. Each patient rated headache severity on a 4-point scale (0 = no headache; 1 = mild pain; 2 = moderate pain; 3 = severe pain). (NCT00898677)
Timeframe: 2 hours after dose

Pain Relief at 2 Hours After Dose

Patients reporting pain relief defined as a reduction of headache severity from grades 2 or 3 (moderate or severe pain) at baseline to grades 0 or 1 (no headache or mild pain) at 2 hours after treatment (NCT00898677)
Timeframe: 2 hours after dose

Time to Relief Within 2 Hours After Dose

Patients reporting time to relief defined as the first time point at which a patient reported headache severity grade 1 or 0 (mild pain or no headache) within 2 hours after dose (NCT00898677)
Timeframe: within 2 hours after dose

No Disability at 2 Hours After the Initial Dose of Test Drug

Patients with no disability at 2 hours after the initial dose of test drug. Functional disability was subjectively rated on a scale from grade 0 to 3: Grade 0 - Normal, Grade 1 - Daily activities mildly impaired, Grade 2 - Daily activities severely impaired, Grade 3 - Unable to carry out daily activities, requires bedrest (NCT00897949)
Timeframe: 2 hours after initial dose of test drug

Pain Free at 2 Hours After the Initial Dose of Test Drug

Patients reporting pain free (defined as a reduction of headache severity to grade 0 [no pain]) at 2 hours after the initial dose of test drug. Pain severity was subjectively rated by patients on a scale from grade 0 to 3: Grade 0 - No headache, Grade 1 - Mild pain, Grade 2 - Moderate pain, Grade 3 - Severe pain. (NCT00897949)
Timeframe: 2 hours after initial dose of test drug

Pain Relief 2 Hours After Treatment for Headache Recurrence

Patients reporting pain relief 2 hours after treatment for headache recurrence (defined as the return of headache to grade 2 or 3 within 24 hours of the initial dose in patients who reported pain relief (grades 0 or 1) at 2 hours). (NCT00897949)
Timeframe: 2 hours after treatment for recurrence

Pain Relief at 2 Hours After the Initial Dose of Test Drug

Patients reporting pain relief (defined as a reduction of headache severity from grades 2/3 at baseline to 0/1) at 2 hours after the initial dose of test drug. Pain severity was subjectively rated by patients on a scale from grade 0 to 3: Grade 0 - No headache, Grade 1 - Mild pain, Grade 2 - Moderate pain, Grade 3 - Severe pain. (NCT00897949)
Timeframe: 2 hours after initial dose of test drug

Use of Escape Medication at 2 Hours After the Initial Dose of Test Drug

(NCT00897949)
Timeframe: 2 hours after initial dose of test drug

Trials

1 trial available for rizatriptan and Addiction, Opioid